| Active substance |
Cagrilintide acetate |
| Also known as |
No alternative names reported |
| Blood pressure |
Can potentially lower blood pressure due to weight loss effects |
| Chemical name |
Cagrilintide acetate |
| Dosage (medical) |
Typically administered as a subcutaneous injection, dosage varying depending on clinical trial phase and specific medical guidelines |
| Dosage (sports) |
Not applicable as not typically used in sports settings |
| Effects |
Promotes weight loss, reduces caloric intake, improves glycemic control |
| FORM |
1 vial x 10 mg |
| Formula |
Not specified |
| Half-life |
Approximately 7 days |
| Hepatotoxicity |
No significant hepatotoxic effects reported |
| Lab Test |
Specific tests for monitoring levels not commonly used in clinical practice |
| Main action |
Reduces appetite and enhances weight loss |
| Side effects |
Potential for gastrointestinal disturbances, injection site reactions, and nausea |
| Storage conditions |
Store in a refrigerator, protect from light |
| Substance class |
Peptide analog |
| Trade name |
Not marketed under a specific trade name yet |
| Use in sports |
Not commonly used for sports enhancement |
| Water Retention |
Minimal to none |
| Manufacturer |
Dragon Pharma |
